GlobeNewswire Inc | Sep 9, 2021 08:00AM EDT

September 09, 2021

WALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today that management will participate in the upcoming H.C. Wainwright 23rd Annual Global Investment Conference. Details of the Companys participation are as follows:

Conference: H.C. Wainwright 23^rd Annual Global Investment ConferenceDates: September 13-15, 2021Format: Fireside chat available on-demand beginning September 13^th at 7:00am ET One-on-one investor meetings

About EntasisEntasis is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0462 (targeting multiple Gram-negative pathogens including Pseudomonas aeruginosa) and ETX0282CPDP (targeting Enterobacteriaceae infections). For more information, visit www.entasistx.com.

Entasis Contacts Company:Kyle Dow Entasis Therapeutics (781) 810-0114 kyle.dow@entasistx.com

Investor Relations:Bruce MackleLifeSci Advisors(929) 469-3859bmackle@lifesciadvisors.com